Since the United States Food and Drug Administration approved exenatide in 2005, it took decades for the American Society of Anesthesiologists (ASA) to identify and address perioperative safety concerns, if any, among patients using glucagon-like pepti…
A debate marked by President Joe Biden’s faltering performance featured clashes over insulin costs, inflation, abortion, immigration, and Jan. 6.
Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes! We’re joined by Karla Lester, a pediatrician and certified life and weight coach. Together, we explore the journey of Lizzie and her mother, Jackie, as they navigate…
I waited in line at the pharmacy, a familiar chain store. The man in front of me waited patiently for the technician to ring up his meds. I overheard her say to him, “$125.00. That includes your insulin.” The man bowed his head and smiled p…
Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes! Join us for a discussion on the critical intersection of diabetes and liver disease. Our guest, Sarah Bauer, a pediatrician, shares her personal journey and insights into …
Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a new KFF analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace…
In this special sponsored episode from Sanofi, we welcome Jennifer Goldman. She is a professor of pharmacy at the Massachusetts College of Pharmacy and Health Sciences, board-certified in advanced diabetes management, and a certified diabetes care and …
The Canadian federal government’s decision to cover diabetes medication and devices under its new pharmacare plan is a significant step forward in improving the quality of life for the millions of Canadians with diabetes, especially those who str…
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
Why bother going to work? If I didn’t work, I wouldn’t get paid, so there was that. But it seemed like a pointless exercise. I would stare at my monitor until it was time to go home. On some level I knew I should be, well, working, but I co…
